NCT06487416View on ClinicalTrials.gov

A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

August 31, 2024

Study Completion Date

October 31, 2024

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Tiotropium Bromide Inhalation Powder

By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.

DRUG

Spiriva®Handihaler®

By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.

Trial Locations (1)

233000

The First Affiliated Hospital of Bengbu Medical University, Bengbu

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY